For beneficiaries to be eligible under the BALANCE Model, providers must attest that they meet certain clinical criteria, including qualifying for a GLP-1 for a currently covered use (such as type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea) or for use to treat obesity based on similar clinical criteria as applied in the Medicare GLP-1 Bridge (Figure 3)
Gastrointestinal Side Effects Over Time Nausea, vomiting, diarrhea, and constipation are the most common side effects of GLP-1 therapy
These are metabolic health questions
How do I get a prescription for tirzepatide or semaglutide
A free access to solid normal diet (Altromin 1324, Genestil, Royaucourt, France) was allowed from day 3